Beyond Cytotoxicity: How Antibody-Peptide Fusions Are Redefining ADC Therapy

Antibody-peptide fusions are emerging as a technical alternative to antibody-drug conjugates (ADCs) by delivering therapeutic peptides directly to target cells without relying on cytotoxic payloads, according to BioXconomy. This approach aims to overcome the toxicity and stability limitations associated with traditional ADCs by utilizing the body’s own cellular machinery to activate the therapeutic agent.

ADCs typically consist of a monoclonal antibody linked to a potent chemical toxin. While effective, BioXconomy reports that these constructs often struggle with “off-target” toxicity, where the toxin is released in healthy tissue, and a narrow therapeutic window that limits dosage.

How do antibody-peptide fusions differ from ADCs?

The primary distinction lies in the payload. ADCs use small-molecule cytotoxins to kill cells. In contrast, antibody-peptide fusions use short chains of amino acids—peptides—that can modulate biological functions or trigger apoptosis without the systemic toxicity typical of chemical poisons, BioXconomy explains.

These fusions leverage the specificity of the antibody to home in on a particular antigen on a cell surface. Once bound, the peptide payload is internalized. BioXconomy notes that these peptides are often designed as “pro-peptides,” meaning they remain inactive until they encounter specific enzymes within the target cell’s lysosome.

This enzymatic cleavage releases the active peptide, ensuring the drug only functions inside the intended cell. This mechanism reduces the risk of the “bystander effect,” where the payload leaks into neighboring healthy cells, a common complication in ADC therapy.

What are the technical advantages of peptide fusions?

BioXconomy identifies several technical hurdles that peptide fusions address more effectively than traditional ADCs:

• Reduced Toxicity: Because peptides are biodegradable and more specific in their action than broad-spectrum cytotoxins, they generally present a lower risk of systemic side effects.
• Improved Solubility: Peptides can be engineered to improve the overall hydrophilicity of the molecule, preventing the aggregation issues that often plague hydrophobic ADC payloads.
• Diverse Mechanisms: While ADCs are primarily designed for cytotoxicity, peptide fusions can be used for a wider range of effects, including inhibiting protein-protein interactions or modulating signaling pathways.

The stability of the linker is also a critical factor. BioXconomy states that the chemical bonds used in antibody-peptide fusions are designed to be stable in the bloodstream but rapidly cleaved upon entering the acidic environment of the endosome or lysosome.

What challenges remain for the technology?

Despite the potential, BioXconomy indicates that peptide fusions face significant hurdles regarding half-life. Peptides are susceptible to rapid degradation by proteases in the blood, which can clear the drug from the system before it reaches the target tumor or tissue.

Researchers are addressing this by modifying the peptide backbone or using “stapled” peptides to increase resistance to enzymatic breakdown. The goal is to balance the stability required for transport with the instability required for release once the drug enters the target cell.

The manufacturing process also differs from ADCs. While ADCs require complex chemical conjugation of a synthetic drug to a protein, antibody-peptide fusions can potentially be produced as a single genetic construct using recombinant DNA technology. BioXconomy suggests this could lead to more homogeneous products with a more consistent drug-to-antibody ratio (DAR) compared to the stochastic mixtures often seen in ADC production.